Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,014 across all filing types
Latest filing 2018-08-24 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
关于将重大资产重组部分配套募集资金项目节余募集资金永久补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 福安药业 (Fuan Pharmaceutical) regarding the permanent supplementation of working capital with surplus funds from a major asset restructuring's supporting fundraising project. It details the background of the fundraising, the use of funds, surplus amounts, approvals by the board and supervisory committee, and opinions from independent directors and financial advisors. The document is a formal announcement about the use of previously raised capital and the company's plan to reallocate surplus funds to working capital. It does not contain full financial statements or comprehensive financial performance data, nor is it a transcript, audit report, or earnings release. It is a regulatory announcement about capital use related to a financing event and asset restructuring. Given the content and length (under 5,000 characters), it fits best as a Capital/Financing Update (CAP) rather than a full report or a simple report publication announcement. Therefore, the classification is CAP with high confidence.
2018-08-24 Chinese
2018年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2018 年半年度报告全文" which translates to "2018 Semi-Annual Report Full Text". It contains detailed financial data, business overview, management discussion and analysis, financial indicators, and other comprehensive information typical of an interim or quarterly report. The document length is 15,000 characters, indicating it is a full report rather than a brief announcement. It includes actual financial statements and substantive financial data for the half-year period ending June 30, 2018. The content includes detailed sections such as company overview, financial data, business analysis, risk factors, and product registration progress, which are characteristic of an Interim / Quarterly Report. Therefore, the document should be classified as an Interim / Quarterly Report (IR). H1 2018
2018-08-24 Chinese
第三届监事会第二十三次会议决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of 福安药业 (Fuan Pharmaceutical Group) regarding the approval of the 2018 semi-annual report and related matters. It includes voting results on the approval of the 2018 half-year report, a special report on the use of raised funds, and other related resolutions. The document is short (1164 characters) and primarily announces the decisions made at the Supervisory Board meeting rather than containing the full semi-annual report or detailed financial data. It also references other announcements published on the China Securities Regulatory Commission designated disclosure website. Therefore, this document is an announcement of meeting resolutions and voting results rather than the report itself or a detailed financial report. The best fitting category is Declaration of Voting Results & Voting Rights Announcements (DVA).
2018-08-24 Chinese
2018年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2018 半年度报告摘要' which translates to '2018 Half-Year Report Summary'. It contains detailed financial data such as revenue, net profit, earnings per share, total assets, and net assets for the half-year period. It also includes management discussion and analysis of business operations, compliance, market development, safety, environmental efforts, and product development. The presence of comprehensive financial figures and operational commentary indicates this is a substantive interim financial report rather than a brief announcement or summary. The document length is about 5010 characters, which is sufficient for a half-year report summary. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2018
2018-08-24 Chinese
2018年半年度报告披露提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (352 characters) indicating that the company's 2018 half-year report will be disclosed on a specified date and website. It explicitly states the report will be published later and directs investors to check the official disclosure site. There is no actual financial data or detailed report content included. According to the 'Menu vs Meal' rule, this is a report publication announcement, not the report itself.
2018-08-24 Chinese
关于2018年半年度募集资金实际存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the actual storage and use of funds raised in the first half of 2018 by 福安药业（集团）股份有限公司. It includes extensive financial data on fundraising amounts, usage, balances, changes in investment projects, and compliance with regulatory requirements. The report references approvals from the China Securities Regulatory Commission and includes detailed tables of fundraising usage, project changes, and investment outcomes. The document is lengthy (15,000 characters) and contains substantive financial data and analysis related to fundraising activities and capital management. This matches the description of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. It is not an announcement of a report, nor a full annual or interim report, but a specialized report on fundraising and capital usage. Therefore, the appropriate classification is CAP with high confidence.
2018-08-24 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.